These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30007818)

  • 1. Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.
    Murphy DG; Tilki D
    Eur Urol; 2018 Oct; 74(4):430-431. PubMed ID: 30007818
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.
    Polders DL; Steggerda M; van Herk M; Nichol K; Witteveen T; Moonen L; Nijkamp J; van der Heide UA
    Acta Oncol; 2015 Jun; 54(6):839-46. PubMed ID: 25591817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer.
    Craig T; Wong E; Bauman G; Battista J; Van Dyk J
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):426-36. PubMed ID: 15890584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment planning for prostate focal laser ablation in the face of needle placement uncertainty.
    Cepek J; Lindner U; Davidson SR; Haider MA; Ghai S; Trachtenberg J; Fenster A
    Med Phys; 2014 Jan; 41(1):013301. PubMed ID: 24387531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Watching, waiting and uncertainty in prostate cancer.
    Bailey DE; Wallace M; Mishel MH
    J Clin Nurs; 2007 Apr; 16(4):734-41. PubMed ID: 17402955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
    Gravis G; Audenet F; Irani J; Timsit MO; Barthelemy P; Beuzeboc P; Fléchon A; Linassier C; Oudard S; Rebillard X; Richaud P; Rouprêt M; Thiery Vuillemin A; Vincendeau S; Albiges L; Rozet F
    Cancer Treat Rev; 2017 Apr; 55():211-217. PubMed ID: 27665366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments for localized prostate cancer.
    Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
    Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of DIR uncertainty on prostate passive-scattering proton therapy dose accumulation.
    Abe Y; Kadoya N; Arai K; Takayama Y; Kato T; Kimura K; Ono T; Nakamura T; Wada H; Kikuchi Y; Jingu K
    Phys Med; 2017 Jul; 39():113-120. PubMed ID: 28625473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of linear and nonlinear programming approaches for "worst case dose" and "minmax" robust optimization of intensity-modulated proton therapy dose distributions.
    Zaghian M; Cao W; Liu W; Kardar L; Randeniya S; Mohan R; Lim G
    J Appl Clin Med Phys; 2017 Mar; 18(2):15-25. PubMed ID: 28300378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate biopsy: what to expect. Here are the benefits, risks, and uncertainties of the only diagnostic procedure that can tell you whether you have prostate cancer.
    Harv Mens Health Watch; 2013 Jan; 17(6):4-5. PubMed ID: 23819189
    [No Abstract]   [Full Text] [Related]  

  • 11. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation.
    Lindsay PE; Van Dyk J; Battista JJ
    Med Phys; 2003 Jul; 30(7):1897-908. PubMed ID: 12906208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue composition and density impact on the clinical parameters for (125)I prostate implants dosimetry.
    Oliveira SM; Teixeira NJ; Fernandes L; Teles P; Vieira G; Vaz P
    Phys Med; 2014 Nov; 30(7):799-808. PubMed ID: 25239870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal Therapy for Prostate Cancer: Getting Ready for Prime Time.
    Abreu AL; Kaneko M; Cacciamani GE; Lebastchi AH
    Eur Urol; 2022 Jan; 81(1):34-36. PubMed ID: 34740501
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive analysis of proton range uncertainties related to stopping-power-ratio estimation using dual-energy CT imaging.
    Li B; Lee HC; Duan X; Shen C; Zhou L; Jia X; Yang M
    Phys Med Biol; 2017 Aug; 62(17):7056-7074. PubMed ID: 28678019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton therapy for prostate cancer online: patient education or marketing?
    Sadowski DJ; Ellimoottil CS; Tejwani A; Gorbonos A
    Can J Urol; 2013 Dec; 20(6):7015-20. PubMed ID: 24331342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deformable image registration and interobserver variation in contour propagation for radiation therapy planning.
    Riegel AC; Antone JG; Zhang H; Jain P; Raince J; Rea A; Bergamo AM; Kapur A; Potters L
    J Appl Clin Med Phys; 2016 May; 17(3):347-357. PubMed ID: 27167289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photosensitizers in prostate cancer therapy.
    Gheewala T; Skwor T; Munirathinam G
    Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coverage-based treatment planning to accommodate delineation uncertainties in prostate cancer treatment.
    Xu H; Gordon JJ; Siebers JV
    Med Phys; 2015 Sep; 42(9):5435-43. PubMed ID: 26328992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric impact of contouring and needle reconstruction uncertainties in US-, CT- and MRI-based high-dose-rate prostate brachytherapy treatment planning.
    Rylander S; Buus S; Pedersen EM; Bentzen L; Tanderup K
    Radiother Oncol; 2017 Apr; 123(1):125-132. PubMed ID: 28284493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary results of focal therapy for prostate cancer using cryoablation.
    Mouraviev V; Johansen TE; Polascik TJ
    J Endourol; 2010 May; 24(5):827-34. PubMed ID: 20443724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.